Clinical efficacy and safety of SB309, a biosimilar recombinant human erythropoietin, in the management of anemia

Alaa Bagalagel1 Center for Health Outcomes and PharmacoEconomic Research, University of Arizona, Tucson, AZ, USA;2 College of Pharmacy, King Abdulaziz University, Jeddah, Saudi Arabia

Abdulaziz Mohammed1 Center for Health Outcomes and PharmacoEconomic Research, University of Arizona, Tucson, AZ, USA;2 College of Pharmacy, King Abdulaziz University, Jeddah, Saudi Arabia

Karen MacDonald3 Matrix 45, Tucson, AZ, USA

Ivo Abraham1 Center for Health Outcomes and PharmacoEconomic Research, University of Arizona, Tucson, AZ, USA;3 Matrix 45, Tucson, AZ, USA;4 Department of Pharmacy Practice and Science, College of Pharmacy;5 Department of Family and Community Medicine, College of Medicine, University of Arizona, Tucson, AZ, USACorrespondence[email protected]

Clinical efficacy and safety of SB309, a biosimilar recombinant human erythropoietin, in the management of anemia

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

Clinical efficacy and safety of SB309, a biosimilar recombinant human erythropoietin, in the management of anemia

Citations (1)

Read on this site (1)

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date